Pfizer CEO: Terms Of ‘Very Lengthy’ TrumpRx Deal Confidential To Avoid Antitrust Issues

By Maaisha Osman / November 4, 2025 at 4:52 PM

Pfizer CEO Albert Bourla said Tuesday (Nov. 4) the company’s drug pricing agreement with the Trump administration remains confidential under the terms of what he described as a “very lengthy deal,” adding that the administration has directed companies to keep the details private to avoid antitrust issues.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.